The goal of the Women's Oncology Program (WON) is: (1) to accelerate the pace and expand the range of fundamental discovery research about women's cancers and (2) to facilitate the translation of new scientific findings into the clinic. WON Members study novel pathways by which hormones and growth factors regulate growth and metastasis of women's cancers;identify potential new therapeutic targets or prognostic indicators for response or resistance to therapy;and perform clinical trials to test efficacy of therapeutic agents in treating these cancers. Program leadership has organized WON around three research themes: (1) steroid hormone action and steroid-dependent cancers;(2) growth factor and cytokine promotion of tumor development and metastasis;and (3) investigator-initiated clinical research and development of novel clinical research tools. Professor of Medicine and Physiology Margaret A. Shupnik, PhD, and Professor of Medicine Paula M. Fracasso, MD, PhD, lead the Program. Dr. Shupnik has expertise in molecular endocrinology and estrogen receptor action, and Dr. Fracasso is an experienced clinical trialist in women's oncology. The Program represents a wide variety of expertise: 22 Members from nine departments in the schools of Medicine and of Engineering, and six Associate Members. With critical CCSG help, seven WON Members have joined the University of Virginia (UVA) since the last renewal, and two Members have been retained. The following areas of support have enabled the success of WON research initiatives, which have become increasingly cancer focused and interactive: funding for faculty recruitment and retention;funding for information exchange forums, such as the CC Seminar Series, WON research meetings, and the Program Retreat;Cancer Center Pilot Project Funds;and support from the UVA Cancer Center Shared Resources. Total extramural funding for the Program exceeds $10.5 million, including nearly $5 million from the National Cancer Institute (NCI). Over the past five years, WON Members have published 317 Program-relevant papers of which 29% were inter-Programmatic and 21% were intra-Programmatic.

Public Health Relevance

; The goal of the Women's Oncology Program (WON) is: (1) to accelerate the pace and expand the range of fundamental discovery research about women's cancers and (2) to facilitate the translation of new scientific findings into the clinic.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA044579-23
Application #
8635289
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-02-01
Budget End
2015-01-31
Support Year
23
Fiscal Year
2014
Total Cost
$10,657
Indirect Cost
$5,180
Name
University of Virginia
Department
Type
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Cruickshanks, Nichola; Zhang, Ying; Hine, Sarah et al. (2018) Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma. Clin Cancer Res :
Balogh, Kristen N; Templeton, Dennis J; Cross, Janet V (2018) Macrophage Migration Inhibitory Factor protects cancer cells from immunogenic cell death and impairs anti-tumor immune responses. PLoS One 13:e0197702
Gonzalez, Phillippe P; Kim, Jungeun; Galvao, Rui Pedro et al. (2018) p53 and NF 1 loss plays distinct but complementary roles in glioma initiation and progression. Glia 66:999-1015
Rodriguez, Anthony B; Peske, J David; Engelhard, Victor H (2018) Identification and Characterization of Tertiary Lymphoid Structures in Murine Melanoma. Methods Mol Biol 1845:241-257
Stowman, Anne M; Hickman, Alexandra W; Mauldin, Ileana S et al. (2018) Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures. Melanoma Res 28:237-245
Melhuish, Tiffany A; Kowalczyk, Izabela; Manukyan, Arkadi et al. (2018) Myt1 and Myt1l transcription factors limit proliferation in GBM cells by repressing YAP1 expression. Biochim Biophys Acta Gene Regul Mech 1861:983-995
Kulling, Paige M; Olson, Kristine C; Olson, Thomas L et al. (2018) Calcitriol-mediated reduction in IFN-? output in T cell large granular lymphocytic leukemia requires vitamin D receptor upregulation. J Steroid Biochem Mol Biol 177:140-148
Carlton, Anne L; Illendula, Anuradha; Gao, Yan et al. (2018) Small molecule inhibition of the CBF?/RUNX interaction decreases ovarian cancer growth and migration through alterations in genes related to epithelial-to-mesenchymal transition. Gynecol Oncol 149:350-360
Borten, Michael A; Bajikar, Sameer S; Sasaki, Nobuo et al. (2018) Automated brightfield morphometry of 3D organoid populations by OrganoSeg. Sci Rep 8:5319
Olson, Kristine C; Kulling Larkin, Paige M; Signorelli, Rossana et al. (2018) Vitamin D pathway activation selectively deactivates signal transducer and activator of transcription (STAT) proteins and inflammatory cytokine production in natural killer leukemic large granular lymphocytes. Cytokine 111:551-562

Showing the most recent 10 out of 539 publications